Clinical Trial Update: [18F]PBR111 and Microglial Activation in Multiple Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating [18F]PBR111 for imaging microglial activation in multiple sclerosis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• [18F]PBR111 (PBR111 fluorine-18 radioligand for translocator protein (TSPO))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Sclerosis | Phase 2 | Status: TERMINATED